Literature DB >> 12904708

Hypercoagulable states and central retinal vein occlusion.

J Michael Lahey1, John J Kearney, Murat Tunc.   

Abstract

Central retinal vein occlusion is a common cause of permanent visual loss. Work up and laboratory evaluation of patients requires the clinician to rule out hypertension, diabetes, hyperlipidemia, and glaucoma. Patients without an identifiable risk factor are often subject to extensive testing for primary and secondary thrombophilias. The purpose this paper is to review the literature to determine which of these tests is associated with central retinal vein occlusion. Antiphospholipid antibodies and elevated plasma homocysteine levels appear to be the tests associated most commonly in patients with central retinal vein occlusion in most controlled studies. Primary thrombophilias are found rarely when screening patients with central retinal vein occlusion. Extensive testing for thrombophilias is not warranted in the vast majority of patients with central retinal vein occlusion. Older patients with any of the common vascular risk factors do not require thrombophilic screening. By carefully selecting the patients who are evaluated for thrombophilias, the likelihood of finding true-positive tests is increased.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904708     DOI: 10.1097/00063198-200309000-00008

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  17 in total

1.  Central retinal vein occlusion in an otherwise healthy child.

Authors:  Kihwang Lee; Yoo-Ri Chung; Ho Min Lew
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

2.  [Bilateral simultaneous central retinal vein occlusion in protein S deficiency].

Authors:  G Tóth; G L Sándor; C Reichel; G Domján; Z Z Nagy; M Ecsedy
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

3.  Increased ER stress as a mechanism of retinal neurovasculopathy in mice with severe hyperhomocysteinemia.

Authors:  Amany Tawfik; Sylvia B Smith
Journal:  Austin J Clin Ophthalmol       Date:  2014-06-16

4.  Hyperhomocysteinemia, as an independent risk factor for retinal venous occlusion in an Indian population.

Authors:  Kapil D Lahiri; Jayanta Dutta; Himadri Datta; Harendra N Das
Journal:  Indian J Clin Biochem       Date:  2012-07-04

5.  Age-related changes in visual function in cystathionine-beta-synthase mutant mice, a model of hyperhomocysteinemia.

Authors:  Minzhong Yu; Gwen Sturgill-Short; Preethi Ganapathy; Amany Tawfik; Neal S Peachey; Sylvia B Smith
Journal:  Exp Eye Res       Date:  2011-12-16       Impact factor: 3.467

6.  Acute central retinal vein occlusion following episode of myopericarditis in an adolescent patient.

Authors:  Ankit Desai; Sandeep Saxena; Levent Akduman
Journal:  BMJ Case Rep       Date:  2013-08-01

7.  Retinal Ganglion Cell Loss and Mild Vasculopathy in Methylene Tetrahydrofolate Reductase (Mthfr)-Deficient Mice: A Model of Mild Hyperhomocysteinemia.

Authors:  Shanu Markand; Alan Saul; Penny Roon; Puttur Prasad; Pamela Martin; Rima Rozen; Vadivel Ganapathy; Sylvia B Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

8.  Central retinal vein occlusion in a young Chinese population: risk factors and associated morbidity and mortality.

Authors:  Jane Zea-Chin Kuo; Chi-Chun Lai; Frank Shih-Chang Ong; Chia-Pang Shih; Ling Yeung; Tun-Lu Chen; Kuan-Jen Chen; Wei-Chi Wu
Journal:  Retina       Date:  2010-03       Impact factor: 4.256

9.  [Retinal vein branch occlusion and palsy of the N. abducens in protein S deficiency].

Authors:  H M Holak; N H Holak; S Holak; S A Holak; S Szymaniec
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

10.  Alterations of retinal vasculature in cystathionine-β-synthase heterozygous mice: a model of mild to moderate hyperhomocysteinemia.

Authors:  Amany Tawfik; Shanu Markand; Mohamed Al-Shabrawey; Jamie N Mayo; Jason Reynolds; Shawn E Bearden; Vadivel Ganapathy; Sylvia B Smith
Journal:  Am J Pathol       Date:  2014-07-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.